Yes its exiting to see .105But given the fundamentals of the company (49 MIL in cash on last quarter, book value of .15 can cents and valid Phase III company) , I really dont see what is extraordinary to reach back the .12 were this stock should be minimally sitting waiting news.
A US biotech company in the same situation would be at least at 150% cash value, which is .225 can cents